New York Eye and Ear Infirmary (NYEE) of Mount Sinai Hospital in Manhattan is the first eye center in the greater New York City area to use BVI’s Leos laser technology in a clinical setting, according to a press release. NYEE ophthalmologist Luis Silva, MD, performed the first Leos endoscopic cyclophotocoagulation (ECP) procedure there on May 6.

“As a glaucoma surgeon with experience in ECP, I was pleased to witness a significant improvement in this technology, with the surgeon now taking complete control of visualization of the ciliary body processes,” Dr. Silva said, adding that Leos may help surgeons approach ECP with greater confidence and consistency.

Leos, which received FDA 510(k) clearance in April 2025, is the only FDA-approved digital endoscopy and laser system designed to reduce intraocular pressure through a minimally invasive ab interno approach while providing digital endoscopic visualization of the eye’s internal anatomy.

“At New York Eye and Ear Infirmary of Mount Sinai, our mission is to lead in the incorporation of advanced technologies that enhance patient care, surgical precision, and clinical education,” James C. Tsai, MD, MBA, president of NYEE and chair of its ophthalmology department, stated in a press release. “By bringing this next-generation digital endoscopy and laser platform to NYEE, we are reconfirming our commitment to offering our surgeons and patients access to innovations and devices that can help advance the future of glaucoma treatment.”

According to BVI, Leos was designed to meet the needs of surgeons who treat a broad range of glaucoma patients, including those in earlier stages of disease. It can also be integrated with cataract procedures.

“NYEE has long stood at the forefront of ophthalmic care, education, and innovation, and we are honored that one of the world’s most respected eye institutions is among the earliest adopters of Leos,” said Jim Hollingshead, president and chief executive officer of BVI. “Partnering with leading institutions like NYEE helps ensure that meaningful technologies reach the surgical teams who are shaping the next era of ophthalmic care.”